References
- Laxminarayan R, Sridhar D, Blaser M, et al. Achieving global targets for antimicrobial resistance. Science. 2016;353(6302):874–875.
- Peterson LR. A review of tigecycline–the first glycylcycline. Int J Antimicrob Agents. 2008;32(Suppl 4):S215–S222.
- Babinchak T, Ellis-Grosse E, Dartois N, Tigecycline 306 Study Group, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005;41(Suppl 5):S354–S67.
- Ellis-Grosse EJ, Babinchak T, Dartois N, Tigecycline 300 c SSG, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41(Suppl 5):S341–S53.
- Tanaseanu C, Bergallo C, Teglia O, 313 Study Group, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;61(3):329–338.
- Jenner L, Starosta AL, Terry DS, et al. Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis. Proc Natl Acad Sci U S A. 2013;110(10):3812–3816.
- Bender JK, Cattoir V, Hegstad K, et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature. Drug Resist Updat. 2018;40:25–39.
- Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011;1:47.
- De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18(3):R90.
- Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11(11):834–844.
- Cui N, Cai H, Li Z, et al. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm. 2019;41(6):1408–1413.
- Zhang Q, Wang J, Liu H, et al. Risk factors for tigecycline-induced hypofibrinogenaemia. J Clin Pharm Ther. 2020;45(6):1434–1441.
- Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2015;59(3):1650–1655.
- Giryes S, Azzam ZS, Ismael-Badarneh R, et al. Severe coagulation disorder and thrombocytopenia associated with tigecycline – case report and review of literature. Curr Drug Saf. 2017;12(1):7–9.
- Gauer RL, Braun MM. Thrombocytopenia. Am Fam Phys. 2012;85(6):612–622.
- Sabanis N, Paschou E, Gavriilaki E, et al. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infect Dis (Lond). 2015;47(10):743–746.
- Liu J, Yan Y, Zhang F. Risk factors for Tigecycline-Associated hypofibrinogenemia. Ther Clin Risk Manag. 2021;17:325–332.
- Xia G, Jiang R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: a retrospective analysis. Medicine (Baltimore). 2020;99(10):e19466.
- Zha L, Pan L, Guo J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and Meta-Analysis. Adv Ther. 2020;37(3):1049–1064.
- Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;43(4):518–524.
- Fan Q, Huang W, Weng Y, et al. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature. Medicine (Baltimore). 2020;99(43):e22638.
- Wu PC, Wu CC. Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. IDCases. 2018;11:56–57.
- Yilmaz Duran F, Yildirim H, Sen EM. A lesser known side effect of tigecycline: hypofibrinogenemia. Turk J Haematol. 2018;35(1):83–84.
- Pieringer H, Schmekal B, Biesenbach G, et al. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol. 2010;89(10):1063–1064.
- Wu X, Zhao P, Dong L, et al. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Medicine (Baltimore). 2017;96(49):e9124.
- Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost. 2012;38(8):865–883.
- Levi M. The coagulant response in sepsis. Clin Chest Med. 2008;29(4):627–642, viii.
- Jenne CN, Kubes P. Platelets in inflammation and infection. Platelets. 2015;26(4):286–292.
- Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114(3):449–458.